Related Experiment Video

Updated: Mar 29, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance
05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

1.1K

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

Irfan A Asangani1, Vijaya L Dommeti2, Xiaoju Wang1

  • 11] Michigan Center for Translational Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA [2] Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA.

Nature
|April 25, 2014
PubMed

Insights

Bromodomain and extraterminal (BET) inhibitors like JQ1 show promise for treating advanced prostate cancer. These inhibitors target BRD4, disrupting androgen receptor signaling and offering a new epigenetic approach for castration-resistant prostate cancer.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Metastatic castration-resistant prostate cancer (CRPC) is driven by deregulated androgen receptor (AR) signaling.
  • Current therapies targeting AR signaling provide limited durable responses due to acquired resistance.

Purpose of the Study:

  • To investigate the efficacy of bromodomain and extraterminal (BET) inhibition as a therapeutic strategy for CRPC.
  • To elucidate the mechanism by which BET inhibitors affect AR signaling in prostate cancer.

Main Methods:

  • Utilized selective small-molecule BET inhibitors (JQ1, I-BET762) targeting BRD4.
  • Assessed sensitivity of AR-signaling-competent CRPC cell lines to BET inhibition.
  • Examined the physical interaction between BRD4 and AR.
  • Investigated the effect of JQ1 on AR recruitment to target gene loci and AR-mediated transcription.
  • Evaluated efficacy in CRPC xenograft mouse models.

Main Results:

  • AR-signaling-competent CRPC cell lines demonstrated preferential sensitivity to BET inhibition.
  • BRD4 physically interacts with the AR N-terminal domain and is disrupted by JQ1.
  • JQ1, functioning downstream of AR, abrogated BRD4 localization and AR-mediated transcription more potently than the direct AR antagonist MDV3100.
  • BET bromodomain inhibition showed greater efficacy than direct AR antagonism in CRPC xenograft models.

Conclusions:

  • BET inhibition represents a novel epigenetic approach for targeting oncogenic drivers in advanced prostate cancer.
  • Targeting BRD4 offers a potent strategy to overcome resistance mechanisms in CRPC.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
68
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

No description available
1.8K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
640
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K